-
1
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.2
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
2
-
-
81355164576
-
Breast cancer statistics
-
DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics. CA Cancer J Clin. 2011;61(6):409-418.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.6
, pp. 409-418
-
-
Desantis, C.1
Siegel, R.2
Bandi, P.3
Jemal, A.4
-
3
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
-
(2000)
Nature
, vol.406
, Issue.6797
, pp. 747-752
-
-
Perou, C.M.1
Sørlie, T.2
Eisen, M.B.3
-
4
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.19
, pp. 10869-10874
-
-
Sørlie, T.1
Perou, C.M.2
Tibshirani, R.3
-
5
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785): 177-182.
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
6
-
-
0024337144
-
Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.
-
(1989)
Science
, vol.244
, Issue.4905
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
-
7
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2011;344(11):783-792.
-
(2011)
N Engl J Med
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
8
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
9
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
-
10
-
-
79955455179
-
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: Epidemiological and clinical data from a population-based cancer registry study
-
Musolino A, Ciccolallo L, Panebianco M, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9):1837-1846.
-
(2011)
Cancer
, vol.117
, Issue.9
, pp. 1837-1846
-
-
Musolino, A.1
Ciccolallo, L.2
Panebianco, M.3
-
11
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743.
-
(2006)
N Engl J Med
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
12
-
-
78049420759
-
Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib
-
Vogel C, Chan A, Gril B, et al. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol. 2010;40(11):999-1013.
-
(2010)
Jpn J Clin Oncol
, vol.40
, Issue.11
, pp. 999-1013
-
-
Vogel, C.1
Chan, A.2
Gril, B.3
-
13
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-726.
-
(2002)
J Clin Oncol
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
14
-
-
17144371333
-
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
-
Baselga J, Carbonell X, Castañeda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-2171.
-
(2005)
J Clin Oncol
, vol.23
, Issue.10
, pp. 2162-2171
-
-
Baselga, J.1
Carbonell, X.2
Castañeda-Soto, N.J.3
-
15
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648.
-
(1999)
J Clin Oncol
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
16
-
-
34247885996
-
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials
-
Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist. 2007;12(4):375-389.
-
(2007)
Oncologist
, vol.12
, Issue.4
, pp. 375-389
-
-
Tripathy, D.1
-
17
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-4274.
-
(2005)
J Clin Oncol
, vol.23
, Issue.19
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
-
18
-
-
77955805622
-
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: Phase II results
-
Michalaki V, Fotiou S, Gennatas S, Gennatas C. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Anticancer Res. 2010;30(7):3051-3054.
-
(2010)
Anticancer Res
, vol.30
, Issue.7
, pp. 3051-3054
-
-
Michalaki, V.1
Fotiou, S.2
Gennatas, S.3
Gennatas, C.4
-
19
-
-
77949893849
-
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer
-
Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:976-983.
-
(2010)
J Clin Oncol
, vol.28
, pp. 976-983
-
-
Wardley, A.M.1
Pivot, X.2
Morales-Vasquez, F.3
-
20
-
-
79951982754
-
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2- gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens
-
Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2- gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29(2):149-156.
-
(2011)
J Clin Oncol
, vol.29
, Issue.2
, pp. 149-156
-
-
Valero, V.1
Forbes, J.2
Pegram, M.D.3
-
21
-
-
74849122823
-
A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial
-
Moulder S, Li H, Wang M, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010;119(3):663-671.
-
(2010)
Breast Cancer Res Treat
, vol.119
, Issue.3
, pp. 663-671
-
-
Moulder, S.1
Li, H.2
Wang, M.3
-
22
-
-
77951918330
-
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial
-
Untch M, Muscholl M, Tjulandin S, et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol. 2010;28(9):1473-1480.
-
(2010)
J Clin Oncol
, vol.28
, Issue.9
, pp. 1473-1480
-
-
Untch, M.1
Muscholl, M.2
Tjulandin, S.3
-
23
-
-
33745530224
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
-
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24(18):2786-2792.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18
, pp. 2786-2792
-
-
Robert, N.1
Leyland-Jones, B.2
Asmar, L.3
-
24
-
-
58149250717
-
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer
-
Yardley DA, Burris HA 3rd, Simons L, et al. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(5):425-431.
-
(2008)
Clin Breast Cancer
, vol.8
, Issue.5
, pp. 425-431
-
-
Yardley, D.A.1
Burris 3rd., H.A.2
Simons, L.3
-
25
-
-
79951974161
-
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study
-
Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29(3):264-271.
-
(2011)
J Clin Oncol
, vol.29
, Issue.3
, pp. 264-271
-
-
Andersson, M.1
Lidbrink, E.2
Bjerre, K.3
-
26
-
-
73949105921
-
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study
-
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529-5537.
-
(2009)
J Clin Oncol
, vol.27
, Issue.33
, pp. 5529-5537
-
-
Kaufman, B.1
Mackey, J.R.2
Clemens, M.R.3
-
27
-
-
65349110371
-
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study
-
Von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol. 2009;27(12):1999-2006.
-
(2009)
J Clin Oncol
, vol.27
, Issue.12
, pp. 1999-2006
-
-
von Minckwitz, G.1
du Bois, A.2
Schmidt, M.3
-
28
-
-
80053362290
-
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
-
Von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47(15):2273-2281.
-
(2011)
Eur J Cancer
, vol.47
, Issue.15
, pp. 2273-2281
-
-
von Minckwitz, G.1
Schwedler, K.2
Schmidt, M.3
-
29
-
-
3042676349
-
Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories
-
discussion 59-62
-
Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5(1):52-58; discussion 59-62.
-
(2004)
Clin Breast Cancer
, vol.5
, Issue.1
, pp. 52-58
-
-
Gelmon, K.A.1
Mackey, J.2
Verma, S.3
-
30
-
-
53149153173
-
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
-
Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast. 2008;17(5):499-505.
-
(2008)
Breast
, vol.17
, Issue.5
, pp. 499-505
-
-
Fabi, A.1
Metro, G.2
Ferretti, G.3
-
31
-
-
80053539103
-
Adjuvant trastuzumab in HER2- positive breast cancer
-
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2- positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
-
(2011)
N Engl J Med
, vol.365
, Issue.14
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
-
32
-
-
80052728749
-
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
-
Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
-
(2011)
J Clin Oncol
, vol.29
, Issue.25
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
-
33
-
-
77954716653
-
Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease
-
author reply e338-e339
-
Ferretti G, Fabi A, Felici A, Papaldo P. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. J Clin Oncol. 2010;28(20):e337. author reply e338-e339.
-
(2010)
J Clin Oncol
, vol.28
, Issue.20
-
-
Ferretti, G.1
Fabi, A.2
Felici, A.3
Papaldo, P.4
-
34
-
-
79957601951
-
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups
-
Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357.
-
(2011)
J Clin Oncol
, vol.29
, Issue.25
, pp. 3351-3357
-
-
Untch, M.1
Fasching, P.A.2
Konecny, G.E.3
-
35
-
-
20544460650
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
-
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676-3685.
-
(2005)
J Clin Oncol
, vol.23
, Issue.16
, pp. 3676-3685
-
-
Buzdar, A.U.1
Ibrahim, N.K.2
Francis, D.3
-
36
-
-
75149145066
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
-
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377-384.
-
(2010)
Lancet
, vol.375
, Issue.9712
, pp. 377-384
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
-
37
-
-
77951624086
-
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro study
-
Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024-2031.
-
(2010)
J Clin Oncol
, vol.28
, Issue.12
, pp. 2024-2031
-
-
Untch, M.1
Rezai, M.2
Loibl, S.3
-
38
-
-
3142678666
-
Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer
-
Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13(3):173-183.
-
(2004)
Breast
, vol.13
, Issue.3
, pp. 173-183
-
-
Suter, T.M.1
Cook-Bruns, N.2
Barton, C.3
-
39
-
-
34548531901
-
Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial
-
Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol. 2007;25(25):3859-3865.
-
(2007)
J Clin Oncol
, vol.25
, Issue.25
, pp. 3859-3865
-
-
Suter, T.M.1
Procter, M.2
van Veldhuisen, D.J.3
-
40
-
-
41649083764
-
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
-
Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-1238.
-
(2008)
J Clin Oncol
, vol.26
, Issue.8
, pp. 1231-1238
-
-
Perez, E.A.1
Suman, V.J.2
Davidson, N.E.3
-
41
-
-
77958453259
-
Eff icacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
-
Costa RB, Kur ra G, Greenberg L, Geyer CE. Eff icacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010; 21(11):2153-2160.
-
(2010)
Ann Oncol
, vol.21
, Issue.11
, pp. 2153-2160
-
-
Costa, R.B.1
Kurra, G.2
Greenberg, L.3
Geyer, C.E.4
-
42
-
-
78651437988
-
Human epidermal growth factor receptor-2- positive breast cancer: Current management of early, advanced, and recurrent disease
-
Callahan R, Hurvitz S. Human epidermal growth factor receptor-2- positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011;23(1):37-43.
-
(2011)
Curr Opin Obstet Gynecol
, vol.23
, Issue.1
, pp. 37-43
-
-
Callahan, R.1
Hurvitz, S.2
-
43
-
-
34247588567
-
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
-
Scaltriti M, Rojo F, Ocaña A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-638.
-
(2007)
J Natl Cancer Inst
, vol.99
, Issue.8
, pp. 628-638
-
-
Scaltriti, M.1
Rojo, F.2
Ocaña, A.3
-
44
-
-
3543146052
-
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
-
Köstler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(5):1618-1624.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1618-1624
-
-
Köstler, W.J.1
Schwab, B.2
Singer, C.F.3
-
45
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852-1857.
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.24
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
Mascarenhas, D.4
Pollak, M.5
-
46
-
-
33947246109
-
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
-
Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13(4):1198-1207.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.4
, pp. 1198-1207
-
-
Harris, L.N.1
You, F.2
Schnitt, S.J.3
-
47
-
-
34548071359
-
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
-
Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007; 13(16):4909-4919.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.16
, pp. 4909-4919
-
-
Ritter, C.A.1
Perez-Torres, M.2
Rinehart, C.3
-
48
-
-
5144226211
-
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
-
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117-127.
-
(2004)
Cancer Cell
, vol.6
, Issue.2
, pp. 117-127
-
-
Nagata, Y.1
Lan, K.H.2
Zhou, X.3
-
49
-
-
77953411708
-
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib
-
O'Brien NA, Browne BC, Chow L, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010;9(6):1489-1502.
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.6
, pp. 1489-1502
-
-
O'Brien, N.A.1
Browne, B.C.2
Chow, L.3
-
50
-
-
35148885729
-
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
-
Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
-
(2007)
Cancer Cell
, vol.12
, Issue.4
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
-
51
-
-
33646372698
-
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
-
Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219-225.
-
(2006)
Breast
, vol.15
, Issue.2
, pp. 219-225
-
-
Stemmler, H.J.1
Kahlert, S.2
Siekiera, W.3
-
52
-
-
4344691784
-
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
-
Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):639-643.
-
(2004)
Br J Cancer
, vol.91
, Issue.4
, pp. 639-643
-
-
Clayton, A.J.1
Danson, S.2
Jolly, S.3
-
53
-
-
0038010542
-
Central nervous systemmetastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
-
Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous systemmetastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972-2977.
-
(2003)
Cancer
, vol.97
, Issue.12
, pp. 2972-2977
-
-
Bendell, J.C.1
Domchek, S.M.2
Burstein, H.J.3
-
54
-
-
46249099391
-
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
-
Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19(7):1242-1248.
-
(2008)
Ann Oncol
, vol.19
, Issue.7
, pp. 1242-1248
-
-
Dawood, S.1
Broglio, K.2
Esteva, F.J.3
-
55
-
-
33751255191
-
Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid
-
Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol. 2006;24(18S):1525.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18 S
, pp. 1525
-
-
Stemmler, J.1
Schmitt, M.2
Willems, A.3
Bernhard, H.4
Harbeck, N.5
Heinemann, V.6
-
56
-
-
62549135630
-
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
-
Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100(6):894-900.
-
(2009)
Br J Cancer
, vol.100
, Issue.6
, pp. 894-900
-
-
Park, Y.H.1
Park, M.J.2
Ji, S.H.3
-
57
-
-
58949099515
-
Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
-
Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol. 2009;20(1):56-62.
-
(2009)
Ann Oncol
, vol.20
, Issue.1
, pp. 56-62
-
-
Park, I.H.1
Ro, J.2
Lee, K.S.3
Nam, B.H.4
Kwon, Y.5
Shin, K.H.6
-
58
-
-
0037068741
-
Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ erbB2 and downstream Erk1/2 and AKT pathways
-
Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255-6263.
-
(2002)
Oncogene
, vol.21
, Issue.41
, pp. 6255-6263
-
-
Xia, W.1
Mullin, R.J.2
Keith, B.R.3
-
59
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-1639.
-
(2006)
Cancer Res
, vol.66
, Issue.3
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
-
60
-
-
33847369020
-
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling
-
Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6(2):667-674.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.2
, pp. 667-674
-
-
Nahta, R.1
Yuan, L.X.2
Du, Y.3
Esteva, F.J.4
-
61
-
-
33847013396
-
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers
-
Xia W, Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007;67(3):1170-1175.
-
(2007)
Cancer Res
, vol.67
, Issue.3
, pp. 1170-1175
-
-
Xia, W.1
Husain, I.2
Liu, L.3
-
62
-
-
30544450275
-
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
-
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005;24(41):6213-6221.
-
(2005)
Oncogene
, vol.24
, Issue.41
, pp. 6213-6221
-
-
Xia, W.1
Gerard, C.M.2
Liu, L.3
Baudson, N.M.4
Ory, T.L.5
Spector, N.L.6
-
63
-
-
60149109196
-
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
-
Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803-814.
-
(2009)
Oncogene
, vol.28
, Issue.6
, pp. 803-814
-
-
Scaltriti, M.1
Verma, C.2
Guzman, M.3
-
64
-
-
11244257032
-
The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer
-
Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005;65(1):18-25.
-
(2005)
Cancer Res
, vol.65
, Issue.1
, pp. 18-25
-
-
Chu, I.1
Blackwell, K.2
Chen, S.3
Slingerland, J.4
-
65
-
-
66149093701
-
Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines
-
Emde AM, Maslak K, Liu H, Reles AE, Possinger K, Eucker J. Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines. J Clin Oncol. 2007;25(18S):14050.
-
(2007)
J Clin Oncol
, vol.25
, Issue.18 S
, pp. 14050
-
-
Emde, A.M.1
Maslak, K.2
Liu, H.3
Reles, A.E.4
Possinger, K.5
Eucker, J.6
-
66
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23):5305-5313.
-
(2005)
J Clin Oncol
, vol.23
, Issue.23
, pp. 5305-5313
-
-
Burris III., H.A.1
Hurwitz, H.I.2
Dees, E.C.3
-
67
-
-
44849108294
-
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
-
Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008;19(6):1068-1074.
-
(2008)
Ann Oncol
, vol.19
, Issue.6
, pp. 1068-1074
-
-
Burstein, H.J.1
Storniolo, A.M.2
Franco, S.3
-
68
-
-
61649118623
-
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
-
Blackwell KL, Pegram MD, Tan-Chiu E, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009;20(6):1026-1031.
-
(2009)
Ann Oncol
, vol.20
, Issue.6
, pp. 1026-1031
-
-
Blackwell, K.L.1
Pegram, M.D.2
Tan-Chiu, E.3
-
69
-
-
70449517339
-
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies
-
Toi M, Iwata H, Fujiwara Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 2009;101(10):1676-1682.
-
(2009)
Br J Cancer
, vol.101
, Issue.10
, pp. 1676-1682
-
-
Toi, M.1
Iwata, H.2
Fujiwara, Y.3
-
70
-
-
46449113024
-
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
-
Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008;26(18):2999-3005.
-
(2008)
J Clin Oncol
, vol.26
, Issue.18
, pp. 2999-3005
-
-
Gomez, H.L.1
Doval, D.C.2
Chavez, M.A.3
-
71
-
-
49149084837
-
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer
-
Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2008;26(20):3317-3323.
-
(2008)
J Clin Oncol
, vol.26
, Issue.20
, pp. 3317-3323
-
-
Storniolo, A.M.1
Pegram, M.D.2
Overmoyer, B.3
-
72
-
-
77949884661
-
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
-
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130.
-
(2010)
J Clin Oncol
, vol.28
, Issue.7
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
-
73
-
-
77949721591
-
Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy
-
Blackwell K, Burstein H, Sledge G, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res. 2009;69(24 Suppl 3):61.
-
(2009)
Cancer Res
, vol.69
, Issue.24 SUPPL 3
, pp. 61
-
-
Blackwell, K.1
Burstein, H.2
Sledge, G.3
-
74
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538-5546.
-
(2009)
J Clin Oncol
, vol.27
, Issue.33
, pp. 5538-5546
-
-
Johnston, S.1
Pippen Jr., J.2
Pivot, X.3
-
75
-
-
79955617130
-
HER2 and hormone receptorpositive breast cancer: Blocking the right target
-
Cortés J, Saura C, Bellet M, et al. HER2 and hormone receptorpositive breast cancer: blocking the right target. Nat Rev Clin Oncol. 2011;8(5):307-311.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, Issue.5
, pp. 307-311
-
-
Cortés, J.1
Saura, C.2
Bellet, M.3
-
76
-
-
0034691674
-
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
-
Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000;19(31):3460-3469.
-
(2000)
Oncogene
, vol.19
, Issue.31
, pp. 3460-3469
-
-
Yen, L.1
You, X.L.2
Moustafa, A.E.A.3
-
77
-
-
0001223491
-
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
-
Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151(6):1523-1530.
-
(1997)
Am J Pathol
, vol.151
, Issue.6
, pp. 1523-1530
-
-
Petit, A.M.1
Rak, J.2
Hung, M.C.3
-
78
-
-
12144291334
-
Association between HER-2/ neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
-
Konecny GE, Meng YG, Untch M, et al. Association between HER-2/ neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706-1716.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1706-1716
-
-
Konecny, G.E.1
Meng, Y.G.2
Untch, M.3
-
79
-
-
1842543455
-
HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF)
-
Abstract 570
-
Epstein M, Ayala R, Tchekmedyian N, Borgstrom P, Pegram M, Slamon D. HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Presented at San Antonio Breast Cancer Symposium 2002, Abstract 570.
-
(2002)
Presented At San Antonio Breast Cancer Symposium
-
-
Epstein, M.1
Ayala, R.2
Tchekmedyian, N.3
Borgstrom, P.4
Pegram, M.5
Slamon, D.6
-
80
-
-
84875053244
-
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
-
Epub December 24, 2011
-
Rugo HS, Jo Chien A, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. Epub December 24, 2011.
-
Breast Cancer Res Treat
-
-
Rugo, H.S.1
Chien, A.J.2
Franco, S.X.3
-
81
-
-
55249101007
-
Randomized study of pazopanib + lapatinib vs lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
-
abstract 1016
-
Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol. 2008;26 Suppl: abstract 1016.
-
(2008)
J Clin Oncol
, Issue.26 SUPPL
-
-
Slamon, D.1
Gomez, H.L.2
Kabbinavar, F.F.3
-
82
-
-
56549113680
-
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses
-
Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533-543.
-
(2008)
Breast Cancer Res Treat
, vol.112
, Issue.3
, pp. 533-543
-
-
Cameron, D.1
Casey, M.2
Press, M.3
-
83
-
-
77957771125
-
Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial
-
Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-934.
-
(2010)
Oncologist
, vol.15
, Issue.9
, pp. 924-934
-
-
Cameron, D.1
Casey, M.2
Oliva, C.3
Newstat, B.4
Imwalle, B.5
Geyer, C.E.6
-
84
-
-
57149096463
-
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
-
Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544-5552.
-
(2008)
J Clin Oncol
, vol.26
, Issue.34
, pp. 5544-5552
-
-
di Leo, A.1
Gomez, H.L.2
Aziz, Z.3
-
85
-
-
68549121149
-
Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer
-
Castañeda CA, Gomez HL. Targeted therapies: combined lapatinib and paclitaxel in HER2-positive breast cancer. Nat Rev Clin Oncol. 2009;6(6):308-309.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.6
, pp. 308-309
-
-
Castañeda, C.A.1
Gomez, H.L.2
-
86
-
-
46449138403
-
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
-
LoRusso PM, Jones SF, Koch KM, et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol. 2008;26(18):3051-3056.
-
(2008)
J Clin Oncol
, vol.26
, Issue.18
, pp. 3051-3056
-
-
Lorusso, P.M.1
Jones, S.F.2
Koch, K.M.3
-
87
-
-
84856227263
-
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
-
Gajria D, Gonzalez J, Feigin K, et al. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2012;131(1):111-116.
-
(2012)
Breast Cancer Res Treat
, vol.131
, Issue.1
, pp. 111-116
-
-
Gajria, D.1
Gonzalez, J.2
Feigin, K.3
-
88
-
-
84862513771
-
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
-
Epub Jul 21
-
Chew HK, Somlo G, Mack PC, et al. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2001. Epub Jul 21.
-
(2001)
Ann Oncol
-
-
Chew, H.K.1
Somlo, G.2
Mack, P.C.3
-
89
-
-
80051495503
-
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial
-
Decensi A, Puntoni M, Pruneri G, et al. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila). 2011;4(8):1181-1189.
-
(2011)
Cancer Prev Res (Phila)
, vol.4
, Issue.8
, pp. 1181-1189
-
-
Decensi, A.1
Puntoni, M.2
Pruneri, G.3
-
90
-
-
41949119777
-
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
-
Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 2008;26(7):1066-1072.
-
(2008)
J Clin Oncol
, vol.26
, Issue.7
, pp. 1066-1072
-
-
Johnston, S.1
Trudeau, M.2
Kaufman, B.3
-
91
-
-
77954745034
-
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer
-
Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010;28(20):3248-3255.
-
(2010)
J Clin Oncol
, vol.28
, Issue.20
, pp. 3248-3255
-
-
Boussen, H.1
Cristofanilli, M.2
Zaks, T.3
Desilvio, M.4
Salazar, V.5
Spector, N.6
-
92
-
-
79951997890
-
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers
-
Dave B, Migliaccio I, Gutierrez MC, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011;29(2):166-173.
-
(2011)
J Clin Oncol
, vol.29
, Issue.2
, pp. 166-173
-
-
Dave, B.1
Migliaccio, I.2
Gutierrez, M.C.3
-
93
-
-
80052895926
-
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy
-
Holmes FA, Nagarwala YM, Espina VA, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol. 2011;29 Suppl:abstract 506.
-
(2011)
J Clin Oncol
-
-
Holmes, F.A.1
Nagarwala, Y.M.2
Espina, V.A.3
-
94
-
-
84856444501
-
Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxanebased chemotherapy (GeparQuinto, GBG 44): A randomised phase 3 trial
-
Untch M, Loibl S, Bischoff J; Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxanebased chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-144.
-
(2012)
Lancet Oncol
, vol.13
, Issue.2
, pp. 135-144
-
-
Untch, M.1
Loibl, S.2
Bischoff, J.3
-
95
-
-
79251587195
-
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
-
Von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301-306.
-
(2011)
Ann Oncol
, vol.22
, Issue.2
, pp. 301-306
-
-
von Minckwitz, G.1
Eidtmann, H.2
Loibl, S.3
-
96
-
-
84857236823
-
NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial
-
Baselga J, Bradbury I, Eidtmann H, et al; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-640.
-
(2012)
Lancet
, vol.379
, Issue.9816
, pp. 633-640
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
-
97
-
-
84868207337
-
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
-
Epub Feb 27
-
Kaklamani VG, Siziopikou K, Scholtens D, et al. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat. 2011. Epub Feb 27.
-
(2011)
Breast Cancer Res Treat
-
-
Kaklamani, V.G.1
Siziopikou, K.2
Scholtens, D.3
-
98
-
-
84867887863
-
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer
-
Epub Oct 18
-
Park IH, Lee KS, Kang HS, et al. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. Invest New Drugs. 2011. Epub Oct 18.
-
(2011)
Invest New Drugs
-
-
Park, I.H.1
Lee, K.S.2
Kang, H.S.3
-
99
-
-
34250174543
-
Brain metastases: The HER2 paradigm
-
Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648-1655.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.6
, pp. 1648-1655
-
-
Lin, N.U.1
Winer, E.P.2
-
100
-
-
4444309646
-
CNS metastases in breast cancer
-
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-3617.
-
(2004)
J Clin Oncol
, vol.22
, Issue.17
, pp. 3608-3617
-
-
Lin, N.U.1
Bellon, J.R.2
Winer, E.P.3
-
101
-
-
34249317254
-
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
-
Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007;67(9):4190-4198.
-
(2007)
Cancer Res
, vol.67
, Issue.9
, pp. 4190-4198
-
-
Palmieri, D.1
Bronder, J.L.2
Herring, J.M.3
-
102
-
-
49449112267
-
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
-
Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100(15):1092-1103.
-
(2008)
J Natl Cancer Inst
, vol.100
, Issue.15
, pp. 1092-1103
-
-
Gril, B.1
Palmieri, D.2
Bronder, J.L.3
-
103
-
-
63149110733
-
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
-
Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.4
, pp. 1452-1459
-
-
Lin, N.U.1
Diéras, V.2
Paul, D.3
-
104
-
-
59149099189
-
Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU)
-
Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol. 2008;26(15S):1094.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15 S
, pp. 1094
-
-
Boccardo, F.1
Kaufman, B.2
Baselga, J.3
-
105
-
-
79952017724
-
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
-
Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625-630.
-
(2011)
Ann Oncol
, vol.22
, Issue.3
, pp. 625-630
-
-
Metro, G.1
Foglietta, J.2
Russillo, M.3
-
106
-
-
84855348673
-
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
-
Bartsch R, Berghoff A, Pluschnig U, et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer. 2012;106(1):25-31.
-
(2012)
Br J Cancer
, vol.106
, Issue.1
, pp. 25-31
-
-
Bartsch, R.1
Berghoff, A.2
Pluschnig, U.3
-
107
-
-
82955163167
-
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
-
Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011;105(3):613-620.
-
(2011)
J Neurooncol
, vol.105
, Issue.3
, pp. 613-620
-
-
Lin, N.U.1
Eierman, W.2
Greil, R.3
-
108
-
-
77649100030
-
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer
-
Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122-129.
-
(2010)
Oncologist
, vol.15
, Issue.2
, pp. 122-129
-
-
Schwartzberg, L.S.1
Franco, S.X.2
Florance, A.3
O'Rourke, L.4
Maltzman, J.5
Johnston, S.6
-
109
-
-
34548222618
-
Lapatinib-associated toxicity and practical management recommendations
-
Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist. 2007;12(7):756-765.
-
(2007)
Oncologist
, vol.12
, Issue.7
, pp. 756-765
-
-
Moy, B.1
Goss, P.E.2
-
110
-
-
44949253343
-
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
-
Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679-686.
-
(2008)
Mayo Clin Proc
, vol.83
, Issue.6
, pp. 679-686
-
-
Perez, E.A.1
Koehler, M.2
Byrne, J.3
Preston, A.J.4
Rappold, E.5
Ewer, M.S.6
-
111
-
-
82355191854
-
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
-
Wu Y, Amonkar MM, Sherrill BH, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011;22(12):2582-2590.
-
(2011)
Ann Oncol
, vol.22
, Issue.12
, pp. 2582-2590
-
-
Wu, Y.1
Amonkar, M.M.2
Sherrill, B.H.3
-
112
-
-
70349912269
-
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment
-
Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009;117(3):577-589.
-
(2009)
Breast Cancer Res Treat
, vol.117
, Issue.3
, pp. 577-589
-
-
Zhou, X.1
Cella, D.2
Cameron, D.3
-
113
-
-
77949496808
-
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer
-
Sherrill B, Di Leo A, Amonkar MM, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin. 2010;26(4):767-775.
-
(2010)
Curr Med Res Opin
, vol.26
, Issue.4
, pp. 767-775
-
-
Sherrill, B.1
di Leo, A.2
Amonkar, M.M.3
|